ID
11728
Beschrijving
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872
Link
https://clinicaltrials.gov/ct2/show/NCT00391872
Trefwoorden
Versies (1)
- 28-07-15 28-07-15 -
Geüploaded op
28 juli 2015
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility PLATO Acute Coronary Syndrome NCT00391872
Eligibility Criteria
- StudyEvent: ODM
Beschrijving
Exclusion Criteria
Beschrijving
moderate or severe liver disease
Datatype
boolean
Alias
- UMLS CUI-1
- C0085605
Beschrijving
treated with blood clotting agents that cannot be stopped
Datatype
boolean
Alias
- UMLS CUI-1
- C0280087
Beschrijving
already been treated with an invasive (angioplasty) procedure
Datatype
boolean
Alias
- UMLS CUI-1
- C0190211
Similar models
Eligibility Criteria
- StudyEvent: ODM